Max Masucci
Stock Analyst at TD Cowen
(0.14)
# 4,415
Out of 5,182 analysts
18
Total ratings
13.64%
Success rate
-32.48%
Average return
Main Sectors:
Stocks Rated by Max Masucci
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BRKR Bruker | Maintains: Hold | $74 → $72 | $36.26 | +98.57% | 1 | Aug 7, 2024 | |
| BLFS BioLife Solutions | Maintains: Outperform | $29 → $25 | $20.90 | +19.62% | 1 | Aug 9, 2023 | |
| GH Guardant Health | Maintains: Outperform | $70 → $53 | $83.09 | -36.21% | 1 | Feb 24, 2023 | |
| QTRX Quanterix | Downgrades: Market Perform | $38 → $18 | $3.34 | +438.92% | 2 | Aug 9, 2022 | |
| BDSX Biodesix | Initiates: Outperform | n/a | $9.95 | - | 2 | Apr 20, 2022 | |
| EVO Evotec SE | Initiates: Outperform | n/a | $2.98 | - | 1 | Nov 29, 2021 | |
| NAUT Nautilus Biotechnology | Initiates: Outperform | n/a | $2.59 | - | 1 | Nov 2, 2021 | |
| MXCT MaxCyte | Initiates: Outperform | n/a | $0.88 | - | 1 | Aug 24, 2021 | |
| CTKB Cytek Biosciences | Initiates: Outperform | n/a | $4.57 | - | 1 | Aug 17, 2021 | |
| RPID Rapid Micro Biosystems | Initiates: Outperform | n/a | $2.46 | - | 1 | Aug 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.27 | - | 1 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $460 → $470 | $126.92 | +270.31% | 4 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $2.73 | +815.75% | 1 | Apr 15, 2021 |
Bruker
Aug 7, 2024
Maintains: Hold
Price Target: $74 → $72
Current: $36.26
Upside: +98.57%
BioLife Solutions
Aug 9, 2023
Maintains: Outperform
Price Target: $29 → $25
Current: $20.90
Upside: +19.62%
Guardant Health
Feb 24, 2023
Maintains: Outperform
Price Target: $70 → $53
Current: $83.09
Upside: -36.21%
Quanterix
Aug 9, 2022
Downgrades: Market Perform
Price Target: $38 → $18
Current: $3.34
Upside: +438.92%
Biodesix
Apr 20, 2022
Initiates: Outperform
Price Target: n/a
Current: $9.95
Upside: -
Evotec SE
Nov 29, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.98
Upside: -
Nautilus Biotechnology
Nov 2, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.59
Upside: -
MaxCyte
Aug 24, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.88
Upside: -
Cytek Biosciences
Aug 17, 2021
Initiates: Outperform
Price Target: n/a
Current: $4.57
Upside: -
Rapid Micro Biosystems
Aug 9, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.46
Upside: -
Jul 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $3.27
Upside: -
Apr 28, 2021
Maintains: Buy
Price Target: $460 → $470
Current: $126.92
Upside: +270.31%
Apr 15, 2021
Initiates: Buy
Price Target: $25
Current: $2.73
Upside: +815.75%